1. Immunology/Inflammation
  2. NO Synthase
  3. iNOs-IN-3

iNOs-IN-3 (Compound 2d) 是一种具有口服活性的一氧化氮合成酶 (iNOS) 抑制剂 (IC50=3.342 µM)。iNOs-IN-3 具有抗炎活性,可用于 LPS 诱导的急性肺损伤 (ALI) 研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

iNOs-IN-3 Chemical Structure

iNOs-IN-3 Chemical Structure

CAS No. : 2241674-94-0

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

iNOs-IN-3 (Compound 2d) is an orally active nitric oxide synthase (iNOS) inhibitor (IC50=3.342 µM). iNOs-IN-3 shows anti-inflammatory activity and can be used in LPS-induced acute lung injury (ALI) research[1].

IC50 & Target

IC50: 3.342 µM (iNOS)[1]

体外研究
(In Vitro)

iNOs-IN-3 (25 μM; 24 h) inhibits LPS-induced RAW 264.7 cells[1].
iNOs-IN-3 (12.5 μM; 24 h) can decrease the expression of iNOS[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: RAW 264.7 microphages
Concentration: 25 μM
Incubation Time: 24 hours
Result: Showed higher inhibitory activity (IC50=14.72 µM) in LPS-induced RAW 264.7 cells.

Cell Viability Assay[1]

Cell Line: RAW 264.7 microphages
Concentration: 12.5 μM
Incubation Time: 24 hours
Result: Inhibited the LPS-induced mRNA expression of iNOS obviously.

Cell Viability Assay[1]

Cell Line: RAW 264.7 microphages
Concentration: 12.5 μM
Incubation Time: 24 hours
Result: Inhibited the expression of TNF-α, IL-6, and IL-1β at 12.5 µM.
体内研究
(In Vivo)

iNOs-IN-3 (oral administration; 12.5 mg/kg; once) treatment shows anti-inflammatory activity against xylene-induced ear edema in mice[1].
iNOs-IN-3 (oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once) protects against LPS-induced acute lung injury[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Xylene-induced mice[1]
Dosage: 12.5 mg/kg
Administration: Oral administration; 12.5 mg/kg; once
Result: Showed better activity than the positive control.
Animal Model: LPS-induced acute lung injury (ALI) mice[1]
Dosage: 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg
Administration: Oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once
Result: Attenuated the pathological lesions dose-dependently, such as decreased inflammatory infiltration and pulmonary congestion. Inhibited LPS-induced lung edema dose-dependently.
分子量

488.55

Formula

C27H24N2O5S

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献

iNOs-IN-3 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
iNOs-IN-3
目录号:
HY-150055
需求量: